AngioDynamics Buys Eximo Medical, for Up To 66M

AngioDynamics以6600万美元价格收购以色列设备初创企业Eximo Medical

2019-11-08 10:22:36 Finsmes

本文共719个字,阅读需2分钟

AngioDynamics, Inc. , a Latham, NY-based provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, acquired Eximo Medical, Ltd., a Rehovot, Israel-based early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform. The deal amounted to $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones. The transaction is being funded exclusively through the use of cash on hand. This transaction expands AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio by adding Eximo’s proprietary laser technology, which has received 510(k) clearance for use in the treatment of Peripheral Artery Disease (PAD). The Eximo technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies. Led by Jim Clemmer, President and Chief Executive Officer, AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. Its diverse product lines include ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. Led by Yoel Zabar, Chief Executive Officer, Eximo has developed laser technology capable of delivering short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perforation through tissue selectivity, of embolization to the patient through the availability of aspiration and is indicated to provide treatment for In-Stent Restenosis (ISR), which is the gradual re-narrowing of the artery after a blockage has been previously treated with a stent. Additionally, the laser technology advances patient treatment options and care by treating a variety of PAD lesion types both above- and below-the-knee. FinSMEs 04/10/2019
AngioDynamics , Inc .,一家位于纽约 Latham 的创新、微创血管通路医疗器械、外周血管疾病和肿瘤医疗提供商,收购了 Eximo Medical , Ltd .,一家总部位于以色列 Rehovot 的早期商业阶段医疗器械公司,及其专有的355nm 波长激光技术平台。 该交易金额为4,600万美元,与某些技术和收入里程碑相关的或有对价最高可达2,000万美元。这笔交易完全是通过使用手头现金进行的。 本次交易通过增加 Eximo 的专有激光技术,扩大了 AngioDynamics 现有的血管介入和治疗( VIT )产品组合,该技术已获得510( k )许可,可用于治疗外周动脉疾病( PAD )。 Eximo 技术补充了 AngioDynamics 领先的血栓管理和静脉不足技术。 在总裁兼首席执行官 Jim Clemmer 的带领下, AngioDynamics 是一家提供微创医疗设备的供应商,专业医疗保健供应商用于血管通路、外周血管疾病和肿瘤治疗。其多元化产品线包括消融系统、血管通路产品、血管造影产品及配件、引流产品、溶栓产品及静脉产品。 在首席执行官 Yoel Zabar 的领导下, Eximo 开发了激光技术,能够在355nm 波长下提供短、高功率脉冲激光能量,而不会损害其光纤电缆在动脉切除过程中的完整性。该技术解决了通过组织选择性穿孔的风险,通过吸气的可得性栓塞病人,并指出提供治疗内 Stent 再狭窄( ISR ),这是动脉阻塞后的逐渐再狭窄先前已用支架治疗。 此外,激光技术进步了病人的治疗选择和护理通过治疗各种类型的 PAD 病变,无论是在膝上和膝下。 FinSME 04/10/2019

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文